// App-Quantinova.ai

3782 : Change in Chronic Low-Grade Nonhematologic Adverse Events (AEs) and Quality of Life (QoL) in Adult Patients (pts) with Philadelphia ChromosomePositive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Switched From Imatinib (IM) to Nilotinib (NIL)

Researchers

Presenter

  • Jorge E. Cortes

Principal Investigators

  • Jeffrey H. Lipton

  • Carole B. Miller

  • Sikander Ailawadhi

  • Luke Akard

  • Javier Pinilla-Ibarz

  • Felice P. Lin

  • Solveig G. Ericson

  • Michael J. Mauro

Medical Centers

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • United States

  • Canada

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • Chronic Myelogenous Leukemia

  • Pancreatitis

  • Hypophosphatemic rickets

  • Cardiac arrest

  • Hyperglycemia

Biomarkers

  • Cluster of Differentiation 206

Drug/Treatment

  • Nilotinib

  • Imatinib

  • IkT001

  • L-Tyrosine

  • lipase

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved